Original ArticlesProfile of psychotropic agents used in autism spectrum disorder according to comorbidities in Turkey: A 4-year evaluationKarabacak, Yurduma; Barun, Sureyyab; Vural, İsmail Mertc; Vural, Elifd; Iseri, Elvane; Kahve, Aybeniz Civanb; Yilmaz, Esra Şafakf; Isli, Fatmag; Turkes, Senab; Ezber, Enesb; Paykal, Gokcenb Author Information aDepartment of Women’s and Reproductive Health, Republic of Turkey Ministry of Health General Directorate of Public Health bDepartment of Medical Pharmacology, Gazi University Faculty of Medicine cDepartment of Pharmacology, Gulhane Faculty of Medicine, University of Health Sciences dDepartment of Medical Pharmacology, Faculty of Medicine, Lokman Hekim University eDepartment of Child and Adolescent Psychiatry and Diseases, Faculty of Medicine, Gazi University fDepartment of Biostatistics, Gulhane Faculty of Medicine, University of Health Sciences gTurkish Medicines and Medical Devices Agency, Ankara, Turkey Received 25 August 2022 Accepted 5 December 2022. Correspondence to Sureyya Barun, MD, Department of Pharmacology, Faculty of Medicine, Gazi University, Ankara, Turkey, Tel: +90 3122024616; e-mail: [email protected] International Clinical Psychopharmacology 38(4):p 216-222, July 2023. | DOI: 10.1097/YIC.0000000000000456 Buy Metrics Abstract It is known that the use of psychotropic pharmaceuticals is common in comorbidities seen in autism spectrum disorder (ASD). We have very limited knowledge about which psychotropic drugs are prescribed when comorbidities are diagnosed in patients with ASD. It is aimed to determine the profile of psychotropic agents in patients diagnosed with ASD associated with comorbidities between the ages of 0–24 in Turkey over 4 years. Data belonging to ASD in Prescription Information System (PIS) was obtained from the ‘Turkish Medicines and Medical Devices Agency’. A total of 34 066 prescriptions including 45 624 psychotropic drugs were analyzed. A total of psychotropic drugs prescribed for patients with ASD was 75.4%. The following psychotropic drugs were prescribed for the patients with ASD and its comorbidities; risperidone (28.6%), aripiprazole (13.7%), and valproic acid (11.3%) are the most preferred psychotropics. The percentage of pharmaceuticals containing psychotropic active substances in prescriptions with ASD and its comorbidities is 7.5%. This study is the first research in which psychotropics used in ASD were evaluated over a wide period and nationwide. Antipsychotics were most commonly prescribed with the diagnosis of ASD. In the presence of ASD and its comorbidities, risperidone was most frequently prescribed. Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.